Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2000 Oct;83(4):334–339. doi: 10.1136/adc.83.4.334

A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide

C Heuck 1, L Heickendorff 1, O Wolthers 1
PMCID: PMC1718508  PMID: 10999872

Abstract

AIMS—To determine effects on short term growth and collagen turnover of adding formoterol (Eformoterol) to half the glucocorticoid dose in children with asthma, treated with inhaled budesonide (Pulmicort Turbuhaler).
DESIGN—A randomised double blind, placebo controlled crossover study with two six-week periods.
SETTING—Outpatient clinic in secondary referral centre.
SUBJECTS—A total of 27 prepubertal children aged 6-13 years.
INTERVENTIONS—Formoterol 12 µg and dry powder budesonide 100 µg twice daily in one period; placebo and dry powder budesonide 200 µg twice daily in the other.
OUTCOME MEASURES—Primary outcome measures were lower leg growth rate, and serum and urine markers of type I and type III collagen turnover. Secondary outcome measures were inflammation markers in serum, and parameters of asthma control.
RESULTS—During budesonide 200 µg twice daily treatment, mean lower leg growth rate was 0.14 mm/week (p = 0.02) lower than during the formoterol and budesonide period. Similar statistically significant effects on markers of collagen turnover were found, whereas inflammation markers and asthma control did not vary statistically significantly between the two periods.
CONCLUSIONS—In children treated with inhaled glucocorticoids, halving the dose and adding formoterol is associated with faster short term growth and an increase in markers of collagen turnover, with no loss of asthma control.



Full Text

The Full Text of this article is available as a PDF (145.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard N., Rungby J., Glerup H., Brixen K., Kassem M., Brincker H., Heickendorff L., Eriksen E. F., Nielsen J. L. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol. 1998 Aug;61(2):128–134. doi: 10.1111/j.1600-0609.1998.tb01073.x. [DOI] [PubMed] [Google Scholar]
  2. Agertoft L., Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J. 1997 Jul;10(7):1507–1512. doi: 10.1183/09031936.97.10071507. [DOI] [PubMed] [Google Scholar]
  3. Birkebaek N. H., Esberg G., Andersen K., Wolthers O., Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child. 1995 Dec;73(6):524–527. doi: 10.1136/adc.73.6.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blumsohn A., Naylor K. E., Assiri A. M., Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem. 1995 Nov;41(11):1592–1598. [PubMed] [Google Scholar]
  5. Bollen A. M., Eyre D. R. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone. 1994 Jan-Feb;15(1):31–34. doi: 10.1016/8756-3282(94)90888-5. [DOI] [PubMed] [Google Scholar]
  6. Colwell A., Eastell R. The renal clearance of free and conjugated pyridinium cross-links of collagen. J Bone Miner Res. 1996 Dec;11(12):1976–1980. doi: 10.1002/jbmr.5650111220. [DOI] [PubMed] [Google Scholar]
  7. Crofton P. M., Wade J. C., Taylor M. R., Holland C. V. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem. 1997 Sep;43(9):1577–1581. [PubMed] [Google Scholar]
  8. Doull I. J., Freezer N. J., Holgate S. T. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med. 1995 Jun;151(6):1715–1719. doi: 10.1164/ajrccm.151.6.7767512. [DOI] [PubMed] [Google Scholar]
  9. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P. D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res. 1995 Apr;10(4):641–649. doi: 10.1002/jbmr.5650100418. [DOI] [PubMed] [Google Scholar]
  10. Hanson D. A., Weis M. A., Bollen A. M., Maslan S. L., Singer F. R., Eyre D. R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992 Nov;7(11):1251–1258. doi: 10.1002/jbmr.5650071119. [DOI] [PubMed] [Google Scholar]
  11. Heuck C., Wolthers O. D. Calculation of knemometric growth rates in group studies of children treated with exogenous glucocorticoids. Ann Hum Biol. 1997 Sep-Oct;24(5):411–418. doi: 10.1080/03014469700005172. [DOI] [PubMed] [Google Scholar]
  12. Heuck C., Wolthers O. D., Hansen M., Kollerup G. Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide. Steroids. 1997 Oct;62(10):659–664. doi: 10.1016/s0039-128x(97)00053-6. [DOI] [PubMed] [Google Scholar]
  13. Heuck C., Wolthers O. D., Kollerup G., Hansen M., Teisner B. Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr. 1998 Nov;133(5):608–612. doi: 10.1016/s0022-3476(98)70098-8. [DOI] [PubMed] [Google Scholar]
  14. Ju H. S., Leung S., Brown B., Stringer M. A., Leigh S., Scherrer C., Shepard K., Jenkins D., Knudsen J., Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem. 1997 Sep;43(9):1570–1576. [PubMed] [Google Scholar]
  15. Kamel S., Brazier M., Rogez J. C., Vincent O., Maamer M., Desmet G., Sebert J. L. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency. J Clin Endocrinol Metab. 1996 Oct;81(10):3717–3721. doi: 10.1210/jcem.81.10.8855828. [DOI] [PubMed] [Google Scholar]
  16. Kristjánsson S., Strannegård I. L., Strannegård O., Peterson C., Enander I., Wennergren G. Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. J Allergy Clin Immunol. 1996 Jun;97(6):1179–1187. doi: 10.1016/s0091-6749(96)70182-3. [DOI] [PubMed] [Google Scholar]
  17. Lugosi E., Halmerbauer G., Frischer T., Koller D. Y. Urinary eosinophil protein X in relation to disease activity in childhood asthma. Allergy. 1997 May;52(5):584–588. doi: 10.1111/j.1398-9995.1997.tb02605.x. [DOI] [PubMed] [Google Scholar]
  18. Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996 Jun;42(6 Pt 1):947–954. [PubMed] [Google Scholar]
  19. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  20. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  21. Pedersen S., O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(39 Suppl):1–34. doi: 10.1111/j.1398-9995.1997.tb05047.x. [DOI] [PubMed] [Google Scholar]
  22. Peterson C. G., Enander I., Nystrand J., Anderson A. S., Nilsson L., Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy. 1991 Sep;21(5):561–567. doi: 10.1111/j.1365-2222.1991.tb00847.x. [DOI] [PubMed] [Google Scholar]
  23. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  24. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  25. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  26. Risteli J., Niemi S., Trivedi P., Mäentausta O., Mowat A. P., Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem. 1988 Apr;34(4):715–718. [PubMed] [Google Scholar]
  27. Risteli J., Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol. 1995;22(2 Suppl):77–81. [PubMed] [Google Scholar]
  28. Robins S. P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M. J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 1994 Oct;9(10):1643–1649. doi: 10.1002/jbmr.5650091019. [DOI] [PubMed] [Google Scholar]
  29. Russell G., Williams D. A., Weller P., Price J. F. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995 Nov;75(5):423–428. [PubMed] [Google Scholar]
  30. Shaw N. J., Fraser N. C., Weller P. H. Asthma treatment and growth. Arch Dis Child. 1997 Oct;77(4):284–286. doi: 10.1136/adc.77.4.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Trivedi P., Risteli J., Risteli L., Hindmarsh P. C., Brook C. G., Mowat A. P. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res. 1991 Sep;30(3):276–280. doi: 10.1203/00006450-199109000-00016. [DOI] [PubMed] [Google Scholar]
  32. Wilding P., Clark M., Thompson Coon J., Lewis S., Rushton L., Bennett J., Oborne J., Cooper S., Tattersfield A. E. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ. 1997 May 17;314(7092):1441–1446. doi: 10.1136/bmj.314.7092.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wolthers O. D., Hansen M., Juul A., Nielsen H. K., Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res. 1997 Jan;41(1):44–50. doi: 10.1203/00006450-199701000-00007. [DOI] [PubMed] [Google Scholar]
  34. Wolthers O. D., Heuck C., Hansen M., Kollerup G. Serum and urinary markers of types I and III collagen turnover during short-term prednisolone treatment in healthy adults. Scand J Clin Lab Invest. 1997 Apr;57(2):133–139. doi: 10.1080/00365519709056381. [DOI] [PubMed] [Google Scholar]
  35. Wolthers O. D., Juul A., Hansen M., Müller J., Pedersen S. The insulin-like growth factor axis and collagen turnover in asthmatic children treated with inhaled budesonide. Acta Paediatr. 1995 Apr;84(4):393–397. doi: 10.1111/j.1651-2227.1995.tb13657.x. [DOI] [PubMed] [Google Scholar]
  36. Wolthers O. D., Konstantin-Hansen K., Pedersen S., Petersen K. E. Knemometry in the assessment of short-term linear growth in a population of healthy school children. Horm Res. 1992;37(4-5):156–159. doi: 10.1159/000182301. [DOI] [PubMed] [Google Scholar]
  37. Wolthers O. D. Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids. Eur Respir J. 1996 Apr;9(4):821–827. doi: 10.1183/09031936.96.09040821. [DOI] [PubMed] [Google Scholar]
  38. Wolthers O. D. Methodological aspects of short-term knemometry in the assessment of exogenous glucocorticosteroid-induced growth suppression in children. Ann Hum Biol. 1997 Nov-Dec;24(6):539–546. doi: 10.1080/03014469700005302. [DOI] [PubMed] [Google Scholar]
  39. Wolthers O. D., Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids. Pediatrics. 1992 May;89(5 Pt 1):839–842. [PubMed] [Google Scholar]
  40. Wolthers O. D., Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. BMJ. 1990 Jul 21;301(6744):145–148. doi: 10.1136/bmj.301.6744.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]
  42. Zimmerman B., Lanner A., Enander I., Zimmerman R. S., Peterson C. G., Ahlstedt S. Total blood eosinophils, serum eosinophil cationic protein and eosinophil protein X in childhood asthma: relation to disease status and therapy. Clin Exp Allergy. 1993 Jul;23(7):564–570. doi: 10.1111/j.1365-2222.1993.tb00895.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES